Fulcrum Therapeutics

FULC58

Penny Stock

$3.00arrow_drop_down9.63%-$0.31

Penny Stock

FULC58

$3.00

arrow_drop_down9.63%-$0.31

Penny Stock

Performance History

Key Stats
Open	$3.57
Prev. Close	$3.56
EPS	-0.34
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$209.04M
PE Ratio	-

	LOW	HIGH
Day Range	3.28	3.66
52 Week Range	2.86	13.70

Ratios







EPS	-0.34

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics Inc (FULC) is a biopharmaceutical company focused on developing and commercializing therapies for genetically defined diseases. The company's mission is to accelerate the development of targeted therapies to improve the lives of patients with serious and rare diseases. Fulcrum Therapeutics is driven by the potential of its unique product platform, which is designed to identify and target the root cause of a disease at the gene level.

Fulcrum Therapeutics has a strong commitment to research and development, with a focus on harnessing the power of gene regulation to develop transformative therapies. The company's lead product candidate, FTX-6058, is currently in clinical development for the treatment of sickle cell disease. Sickle cell disease is a genetic disorder that affects the shape and function of red blood cells, leading to various complications.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Alexander C. Sapir
Headquarters: Cambridge
Employees: 89
Exchange: NASDAQ

Keep an eye on Fulcrum Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Fulcrum Therapeutics 's (FULC) price per share?

The current price per share for Fulcrum Therapeutics (FULC) is $3. The stock has seen a price change of -$0.32 recently, indicating a -9.64% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Fulcrum Therapeutics (FULC)?

For Fulcrum Therapeutics (FULC), the 52-week high is $13.7, which is 355.91% from the current price. The 52-week low is $2.86, the current price is 4.89% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Fulcrum Therapeutics (FULC) a growth stock?

Fulcrum Therapeutics (FULC) has shown an average price growth of -4.94% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Fulcrum Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Fulcrum Therapeutics (FULC) stock price performance year to date (YTD)?

As of the latest data, Fulcrum Therapeutics (FULC) has a year-to-date price change of -58.32%. Over the past month, the stock has experienced a price change of -15.83%. Over the last three months, the change has been -66.69%. Over the past six months, the figure is -62.01%. Looking at a longer horizon, the five-year price change stands at -60.67%.

help

Is Fulcrum Therapeutics (FULC) a profitable company?

Fulcrum Therapeutics (FULC) has a net income of -$97.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 22.57% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 65.62% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.8M, although specific revenue growth data is currently not available. The gross profit is $633K. Operating income is noted at -$110.66M. Furthermore, the EBITDA is -$30.88M.

help

What is the market capitalization of Fulcrum Therapeutics (FULC)?

Fulcrum Therapeutics (FULC) has a market capitalization of $189.39M. The average daily trading volume is 3.04, indicating the stock's liquidity and investor engagement.

News

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

FULCRUM THERAPEUTICS

STOCK OPTIONS

NEW EMPLOYEES

BIOPHARMACEUTICAL COMPANY

Oct 11, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BIOHAVEN

TRORILUZOLE

SPINOCEREBELLAR ATAXIA

RARE NEUROLOGICAL DISEASE

Sep 24, 2024

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal